NCT04925609 2025-12-05Briga-PEDPrincess Maxima Center for Pediatric OncologyPhase 1/2 Recruiting65 enrolled
NCT04094610 2025-11-19A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsTurning Point Therapeutics, Inc.Phase 1/2 Recruiting75 enrolled
NCT05160922 2025-09-03Crizotinib Continuation Clinical StudyPfizerPhase 4 Active not recruiting27 enrolled
NCT01524926 2023-12-11CREATEEuropean Organisation for Research and Treatment of Cancer - EORTCPhase 2 Completed582 enrolled
NCT01742286 2020-06-09Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)NovartisPhase 1 Completed83 enrolled 30 charts
NCT02465528 2019-12-27Ceritinib Rare Indications Study in ALK+ TumorsNovartisPhase 2 Terminated22 enrolled 16 charts